How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Dan Nathan is the principal of RiskReversal Advisors, founded in 2016, offering consulting services to investment banks, investment advisors, and private companies. Dan is the co-founder of ...
Dan Gallagher is a columnist for The Wall Street Journal’s Heard on the Street, where he covers the technology and media industries. His work for the Heard column spans the businesses of artificial ...
Ars Technica has been separating the signal from the noise for over 25 years. With our unique combination of technical savvy and wide-ranging interest in the technological arts and sciences, Ars is ...
Key data is currently not available. Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. *Data is provided by Barchart.com. Data reflects weightings calculated at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results